A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults

Vaccine

Volumn 29, Issue 1, 2010, Pages 45-50

  Booy, Robert ^a   Van Der Meeren, Olivier ^b   Ng, Su Peing ^b   Celzo, Froilan ^c   Ramakrishnan, Gunasekaran ^b   Jacquet, Jeanne Marie ^b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Booster; Diphtheria; Pertussis; Tetanus; Vaccination

Indexed keywords

ADT; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PERTUSSIS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; SEROLOGY; SINGLE DRUG DOSE; SKIN REDNESS; TETANUS; TREATMENT RESPONSE;

ADULT; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED;

EID: 78649714015     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.025     Document Type: Article

References (26)

1. Cherry J.D. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005, 115(5):1422-1427.
2. Hewlett E.L., Edwards K.M. Clinical practice. Pertussis-not just for kids. N Engl J Med 2005, 352(12):1215-1222.
3. Lee G.M., Lett S., Schauer S., LeBaron C., Murphy T.V., Rusinak D., et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 2004, 39(11):1572-1580.
4. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005, 24(Suppl. 6):S104-S108.
5. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., et al. Infant pertussis: who was the source?. Pediatr Infect Dis J 2004, 23(11):985-989.
6. Wendelboe A.M., Njamkepo E., Bourillon A., et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007, 26(4):293-299.
7. Wood N., McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev 2008, 9(3):201-211.
8. Chuk L.M., Lambert S.B., May M.L., Beard F.H., Sloots T.P., Selvey C.E., et al. Pertussis in infants: how to protect the vulnerable?. Commun Dis Intell 2008, 32(4):449-456.
9. McIntyre P., Wood N. Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis 2009, 22(3):215-223.
10. Australian immunisation handbook 2008, National Health and Medical Research Council. 9th ed.
11. Sänger R., Behre U., Krause K.H., Loch H.P., Soemantri P., Herrmann D., et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 2007, 166(12):1229-1236.
12. Grimprel E., von Sonnenburg F., Sänger R., Abitbol V., Wolter J.M., Schuerman L.M. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005, 23(28):3657-3667.
13. Vergara R., Tregnaghi M., Ussher J., Navarro S., Rüttimann R., Potin M., et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 2005, 164(6):377-382.
14. Zepp F., Habermehl P., Knuf M., Mannhardt-Laakman W., Howe B., Friedland L.R. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine 2007, 25(29):5248-5252.
15. Zepp F., Knuf M., Habermehl P., Mannhardt-Laakmann W., Howe B., Friedland L.R. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 2006, 149(5):603-610.
16. Turnbull F.M., Heath T.C., Jalaludin B.B., Burgess M.A., Ramalho A.C. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2001, 19:628-636.
17. McIntyre P.B., Turnbull F.M., Egan A.M., Burgess M.A., Wolter J.M., Schuerman L.M., et al. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 2004, 23(3):380-385.
18. McIntyre P.B., Burgess M.A., Egan A., Schuerman L., Hoet B. Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine 2009, 27(7):1062-1066.
19. Schmitt H.J., von König C.H., Neiss A., Bogaerts H., Bock H.L., Schulte-Wissermann H., et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996, 275:37-41.
20. Schmitt H.J., Schuind A., Knuf M., Beutel K., Schulte-Wissermann H., Gahr M., et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr 1996, 129:695-701.
21. Van Damme P., Burgess M. Immunogenicity of a combined diphtheria tetanus-acellular pertussis vaccine in adults. Vaccine 2004, 22:305-308.
22. Granström M., Granström G. Serological correlates in whooping cough. Vaccine 1993, 11(4):445-448.
23. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16(20):1907-1916.
24. Theeten H., Van Damme P., Hoppenbrouwers K., Vandermeulen C., Leback E., Sokal E.M., et al. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine 2005, 10, 23(12):1515-1521.
25. Mertsola J., Van Der Meeren O., He Q., Linko-Parvinen A., Ramakrishnan G., Mannermaa L., et al. The decennial administration of a reduced antigen content diphtheria, tetanus, acellular pertussis vaccine in young adults. Clin Infect Dis 2010, 51:656-662.
26. Knuf M., Vetter V., Celzo F., Van Der Meeren O. The repeated administration of a reduced antigen content diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV) in adolescents. 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) 2009, Abstract 1607.